Key result
Ventricular assist device support successfully bridged 66.7% (4 of 6) of patients with giant cell myocarditis to heart transplantation, with 100% post-transplant survival at 5.7 years.
Why the study?
Does ventricular assist device support successfully bridge patients with giant cell myocarditis to orthotopic heart transplantation?
Population
6 patients with giant cell myocarditis requiring ventricular assist device support, mean age 44 ± 18 years.
Design
Case_series
Follow-up
mean 5.7 ± 4.1 years
Authors
Loading...
VAD bridging to OHT may be feasible in GCM; leaves open questions on survival and optimal timing pending larger prospective data.
Observational (n=6)
Does ventricular assist device support successfully bridge patients with giant cell myocarditis to orthotopic heart transplantation?
VAD support is a viable bridge to heart transplantation for end-stage giant cell myocarditis, yielding good long-term survival despite high rates of post-transplant rejection and disease recurrence.
Murray et al. (2012) conducted an observational in Giant cell myocarditis (n=6). Ventricular assist device (VAD) support was evaluated on Bridged to orthotopic heart transplantation (OHT). Ventricular assist device support successfully bridged 66.7% (4 of 6) of patients with giant cell myocarditis to heart transplantation, with 100% post-transplant survival at 5.7 years.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: